New PET tracer aims to spot Parkinson's protein in the brain
NCT ID NCT06891703
First seen Nov 19, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This early-phase study tests a new radioactive tracer called [18F]ACI-15916, designed to detect clumps of α-synuclein protein in the brain using PET scans. These protein deposits are linked to Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. The trial will include 46 people—both healthy volunteers and those with suspected α-synuclein-related conditions—to check if the tracer is safe and can reliably show differences in protein buildup between groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karolinska Institutet
RECRUITINGSolna, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]ACI-15916 (a radioactive imaging agent)
What this could lead to
If successful, this could lead to a reliable brain scan to diagnose diseases like Parkinson's and Lewy body dementia earlier and more accurately.
What could go wrong
This is a very early Phase 1 study with only 46 participants. The tracer may not bind well to α-synuclein or may cause side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.